Merck (MRK) Gross Margin (2009 - 2026)
Merck's (MRK) quarterly Gross Margin came in at 73.54% in Q2 2026, down 396.0% year-over-year from 24.84% in Q2 2025, and down 0.95% quarter-over-quarter from 74.24% in Q1 2026.
Analysis
Merck (MRK) Gross Margin (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Gross Margin for 18 consecutive years, with 73.54% the latest figure, recorded in Q2 2026.
- On a quarterly basis, Gross Margin fell 396.0% year-over-year to 73.54% in Q2 2026; TTM through Jun 2026 was 72.97%, a 364.0% decrease from a year earlier, with the FY2025 full-year figure at 74.8%, down 152.0% from the prior year.
- Gross Margin was 73.54% for Q2 2026 at Merck, down from 74.24% in the prior quarter.
- Over five years, Gross Margin peaked at 77.98% in Q1 2025 and troughed at 66.15% in Q4 2025.
- A 5-year average of 73.78% and a median of 73.62% in 2022 frame the typical range for Gross Margin.
- Across the five-year window, Gross Margin jumped 673 bps in 2023 and slumped 935 bps in 2025, its largest moves.
- Over 5 years, Gross Margin stood at 71.94% in 2022, then grew by 2 bps to 73.26% in 2023, then climbed by 3 bps to 75.5% in 2024, then fell by 12 bps to 66.15% in 2025, then advanced by 11 bps to 73.54% in 2026.
- The last three Gross Margin figures came in at 73.54% (Q2 2026), 74.24% (Q1 2026), and 66.15% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 68.19% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 74.74% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 73.54% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 78.02% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 72.78% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 80.05% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 93.73% |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 87.30% |
| 10 | Jazz Pharmaceuticals | 16.02 Bn | 14.40 Bn | 1.09 Bn | 90.37% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 73.54% |
| Mar 31, 2026 | 74.24% |
| Dec 31, 2025 | 66.15% |
| Sep 30, 2025 | 77.69% |
| Jun 30, 2025 | 77.50% |
| Mar 31, 2025 | 77.98% |
| Dec 31, 2024 | 75.50% |
| Sep 30, 2024 | 75.51% |
| Jun 30, 2024 | 76.76% |
| Mar 31, 2024 | 77.56% |
| Dec 31, 2023 | 73.26% |
| Sep 30, 2023 | 73.29% |
| Jun 30, 2023 | 73.24% |
| Mar 31, 2023 | 72.90% |
| Dec 31, 2022 | 71.94% |
| Sep 30, 2022 | 73.70% |
| Jun 30, 2022 | 71.11% |
| Mar 31, 2022 | 66.17% |
| Dec 31, 2021 | 71.35% |
| Sep 30, 2021 | 73.77% |